Picture loading failed.

Pre-Made Vatelizumab biosimilar, Whole mAb, Anti-ITGA2 Antibody: Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-615-1mg 1mg 3090
GMP-Bios-ab-615-10mg 10mg Inquiry
GMP-Bios-ab-615-100mg 100mg Inquiry
GMP-Bios-ab-615-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vatelizumab biosimilar, Whole mAb, Anti-ITGA2 Antibody: Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 therapeutic antibody
INN Name Vatelizumab
TargetITGA2
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesChromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis
Development Techna